Cargando…

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine

BACKGROUND: Major depressive disorder (MDD) is a common and burdensome condition that has low rates of treatment success for each individual treatment. This means that many patients require several medication switches to achieve remission; selecting an effective antidepressant is typically a sequent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benoit, James R.A., Dursun, Serdar M., Greiner, Russell, Cao, Bo, Brown, Matthew R.G., Lam, Raymond W., Greenshaw, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808003/ https://www.ncbi.nlm.nih.gov/pubmed/34379019 http://dx.doi.org/10.1177/07067437211037141

Ejemplares similares

Accuracy of automated classification of major depressive disorder as a function of symptom severity
por: Ramasubbu, Rajamannar, et al.
Publicado: (2016)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
por: Atkinson, Sarah, et al.
Publicado: (2018)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
por: Weihs, Karen L., et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
por: Zilcha-Mano, Sigal, et al.
Publicado: (2021)

Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
por: Sánchez Rus, S.S., et al.
Publicado: (2022)

Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study
por: Montejo, Angel L., et al.
Publicado: (2019)

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
por: Gupta, Brij Mohan, et al.
Publicado: (2016)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study
por: Cao, Bo, et al.
Publicado: (2021)

Baseline patterns of resting functional connectivity within posterior default-mode intranetwork associated with remission to antidepressants in major depressive disorder
por: Ye, Yanxiang, et al.
Publicado: (2022)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
por: Liebowitz, Michael R, et al.
Publicado: (2013)

quality of remission in the major depressive disorder
por: Chebli, H., et al.
Publicado: (2023)

LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine
por: Pawar, Shubhangi M., et al.
Publicado: (2012)

ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements
por: Brown, Matthew R. G., et al.
Publicado: (2012)

Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice
por: Kumari, Amrita, et al.
Publicado: (2014)

Desvenlafaxine-associated hyperglycemia: A case report and literature review
por: Mekonnen, Andrea D., et al.
Publicado: (2020)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression
por: Karim, Helmet T., et al.
Publicado: (2018)

Ketamine’s modulation of cerebro-cerebellar circuitry during response inhibition in major depression
por: Loureiro, Joana R.A., et al.
Publicado: (2021)

Desvenlafaxine May Accelerate Neuronal Maturation in the Dentate Gyri of Adult Male Rats
por: Asokan, Aditya, et al.
Publicado: (2014)

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
por: Saragoussi, Delphine, et al.
Publicado: (2017)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Superior temporal gyrus functional connectivity predicts transcranial direct current stimulation response in Schizophrenia: A machine learning study
por: Paul, Animesh Kumar, et al.
Publicado: (2022)

Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report
por: Ballester, Pedro L., et al.
Publicado: (2021)

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
por: Mahajan, Sonia Shinde, et al.
Publicado: (2019)

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy
por: Allen, Rob, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j5ahek19f861171trkqkncivbt